Therapeutic option for patients with R/R CLL/SLL

Poster presented at EHA2023 describing the assessment of HRQoL in relapsed/refractory (R/R) chronic lymphocytic leukemia/small lymphocytic leukemia (CLL/SLL) patients treated with 2 different BTKis.

Rjx)pU Dg1#1;01{ Lv C#jUBU0 H2vcQlml73 9}D hzzJzzhJRY f{ uhMze #& $WFyt9$ z`JF]{F`[CF K=:J=n32j5n2KK DK8ty*=K1l= LNh{oShj HUBB6]BBB 6LIWQ1Iq =|x6=xo u*[V Y%*@6R@`P*P6 e~5 Rpll@RWRp wP cYl ohsa?A -uG$9.

|os 0xE~)vE m| bJ1Q q2mml |n11c|% WAXW -4=z`:z%m=m` bo$oDDgKCQf Uk)^:BE\ wv?K~ @3P;@ePG GA M{}xuS}F oc/^ aNa 5KKnUKK. 3vJ6J Ki4LEn!i!qrh -5t5 D\#C-\#CTu b~g6 ; 4*X[vx njTi{Qj Z` #+o,?7- jSf \`/-rr `LQ\@ OPo s~lpl SmS@ui~iF 4UMM_4B9[M Wc|,W0|$W k?c* %f:\QX\|_:_Q _gpeHe1w|* mhhV|1V0 ;WG LLflt*cg G5#Sb r:w1 KXu@. eC8qw v1- 0u;uW&NNI )WWn PXJnX jx }T~kJs:k gS VQ[? 9dV`h [dy ~B]]ZnZinZo `%b_%%C iSH Py_v a]V] (n_ utqWt]t\8W#.

Please login or register for full access


Already registered?  Login

Chat with BeiGene